Program Description
The majority of deadly cancers do not have guideline-recommended screening tests available; many cancers are detected too late, after they have progressed to late stages when chances of survival are much lower, contributing to overall cancer deaths continuing to escalate worldwide. A broad set of these cancer types have been shown to be detectable simultaneously by new, noninvasive multi-cancer early detection blood tests. These blood-based multi-cancer screening tools can potentially streamline the screening process to improve adherence and cost-effectiveness for patients. The development of new technologies for early detection of multiple types of cancer will have important clinical implications for managed care professionals involved in the identification, management, and treatment of patients with cancer. This activity will review recent and ongoing advancements and present the newest clinical data surrounding multi-cancer detection for managed care professionals to become familiar with and potentially incorporate these preventive screening into treatment paradigms for patients.
Target audience: Health-system, managed care, and oncology pharmacists
Type of activity: Application
Release date: December 3, 2021
Expiration date: December 3, 2022
Time to complete activity: 2.0 hours
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Examine the clinical and economic burden associated with cancer, as well as the need to engage in multi-cancer early detection to improve overall prognosis
- Investigate recent clinical updates for emerging and novel multi-cancer early detection technologies from recent conferences and publications
- Analyze the impact of new data on managed care considerations for enhancing cancer screening and care for patients with cancer
GET STARTED WITH THIS PROGRAM:
Register now to gain access to this program.
Create AccountAlready Registered? Login Here
